Barriers to initiate buprenorphine and methadone for opioid use disorder treatment with postdischarge treatment linkage

8Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Hospitals are an essential site of care for people with opioid use disorder (OUD). Buprenorphine and methadone are underutilized in the hospital. Objectives: Characterize barriers to in-hospital buprenorphine or methadone initiation to inform implementation strategies to increase OUD treatment provision. Design, Settings, and Participants: Survey of hospital-based clinicians' perceptions of OUD treatment from 12 hospitals conducted between June 2022 and August 2022. Measures: Survey questions were grouped into six domains: (1) evidence to treat OUD, (2) hospital processes to treat OUD, (3) buprenorphine or methadone initiation, (4) clinical practices to treat OUD, (5) leadership prioritization of OUD treatment, and (6) job satisfaction. Likert responses were dichotomized and associations between “readiness” to initiate buprenorphine or methadone and each domain were assessed. Results: Of 160 respondents (60% response rate), 72 (45%) reported higher readiness to initiate buprenorphine compared to methadone, 55 (34%). Respondents with higher readiness to initiate medications for OUD were more likely to perceive that evidence supports the use of buprenorphine and methadone to treat OUD (p

Cite

CITATION STYLE

APA

Calcaterra, S. L., Lockhart, S., Natvig, C., & Mikulich, S. (2023). Barriers to initiate buprenorphine and methadone for opioid use disorder treatment with postdischarge treatment linkage. Journal of Hospital Medicine, 18(10), 896–907. https://doi.org/10.1002/jhm.13193

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free